Today’s patent owners face two significant problems when doing business in Asia: the expiration of their patents and Asia’s generally pro-generic stance on pharmaceuticals.  This article explores the broad concept of “evergreening,” which is even more crucial for companies operating in Asia, and a notable exception to the pro-generic policies in the region, the TRIPS+ or the “exclusive rights” approach.